These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France]. Bégaud B; Evreux JC; Jouglard J; Lagier G Therapie; 1985; 40(2):111-8. PubMed ID: 4002188 [No Abstract] [Full Text] [Related]
23. National adverse drug reaction reporting. 1984-1989. Faich GA Arch Intern Med; 1991 Aug; 151(8):1645-7. PubMed ID: 1872669 [TBL] [Abstract][Full Text] [Related]
24. [Drug-induced discoloration of the teeth and gingiva]. Mosimann P; Hartmann K; Kuhn M Praxis (Bern 1994); 1998 Mar; 87(12):413-6. PubMed ID: 9564238 [TBL] [Abstract][Full Text] [Related]
25. [Dementia and memory]. Tissot R Encephale; 1973; 62(6):491-505. PubMed ID: 4805542 [No Abstract] [Full Text] [Related]
26. Current French system of post-marketing drug surveillance. Albengres E; Gauthier F; Tillement JP Int J Clin Pharmacol Ther Toxicol; 1990 Jul; 28(7):312-4. PubMed ID: 2387656 [TBL] [Abstract][Full Text] [Related]
27. [Subjective memory complaints in older people. Is it a symptom of dementia?]. Vogel A Ugeskr Laeger; 2008 May; 170(20):1728-33. PubMed ID: 18489886 [TBL] [Abstract][Full Text] [Related]
28. [Information centers on undesirable effects of drugs: also on alerting function]. Bégaud B; Péré JC; Tubert P; Barat C; Haramburu F; Albin H Therapie; 1987; 42(2):231-7. PubMed ID: 3617000 [No Abstract] [Full Text] [Related]
29. Adverse drug reaction monitoring in pediatric practice. Kshirsagar NA; Karande S Indian Pediatr; 1996 Dec; 33(12):993-8. PubMed ID: 9141798 [No Abstract] [Full Text] [Related]
30. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers. Bennett CL; Nebeker JR; Yarnold PR; Tigue CC; Dorr DA; McKoy JM; Edwards BJ; Hurdle JF; West DP; Lau DT; Angelotta C; Weitzman SA; Belknap SM; Djulbegovic B; Tallman MS; Kuzel TM; Benson AB; Evens A; Trifilio SM; Courtney DM; Raisch DW Arch Intern Med; 2007 May; 167(10):1041-9. PubMed ID: 17533207 [TBL] [Abstract][Full Text] [Related]
31. [Advantages of a microcomputer system in researching duplicated reports]. Biour M; Wagniart F; Jablonka J; Hamel JD; Weissenburger J; Cheymol G Therapie; 1986; 41(5):383-4. PubMed ID: 3810530 [No Abstract] [Full Text] [Related]
32. America's other drug problem. Katz IR; Streim JE Provider; 1994 Nov; 20(11):70, 73. PubMed ID: 10172163 [No Abstract] [Full Text] [Related]
33. Measuring adverse drug reactions in a postmarketing surveillance system. Fisher S; Bryant SG; Kluge RM Psychopharmacol Bull; 1986; 22(1):272-7. PubMed ID: 3726073 [No Abstract] [Full Text] [Related]
35. Adverse drug reactions in hospital patients. Buechner JS Med Health R I; 1998 Feb; 81(2):60-1. PubMed ID: 9505068 [No Abstract] [Full Text] [Related]
36. Early postmarketing drug safety surveillance: data mining points to consider. Hauben M Ann Pharmacother; 2004 Oct; 38(10):1625-30. PubMed ID: 15304626 [TBL] [Abstract][Full Text] [Related]
37. Assessment of the clinical and economic outcomes of pharmacy interventions in drug-related problems. Westerlund T; Marklund B J Clin Pharm Ther; 2009 Jun; 34(3):319-27. PubMed ID: 19646078 [TBL] [Abstract][Full Text] [Related]
38. International monitoring for adverse drug reactions of long latency. Fletcher AP; Griffin JP Adverse Drug React Toxicol Rev; 1991; 10(4):209-30. PubMed ID: 1793771 [No Abstract] [Full Text] [Related]
39. An underrecognized challenge in evaluating postmarketing drug safety. Roden DM Circulation; 2005 Jan; 111(3):246-8. PubMed ID: 15668350 [No Abstract] [Full Text] [Related]
40. Medication administration: how safe is your patient? Am J Nurs; 1995 Oct; 95(10):44-59; quiz 60. PubMed ID: 7573208 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]